{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:06:19Z","timestamp":1792267579425,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bioorg.2020.104218","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T15:15:29Z","timestamp":1598973329000},"page":"104218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents"],"prefix":"10.1016","volume":"104","author":[{"given":"Mohamed Ayman","family":"El-Zahabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmy","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled.","family":"El-Adl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"Abdelraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally I.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Elkady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bioorg.2020.104218_b0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0167-5699(99)01531-5","article-title":"Thalidomide as an emerging immunotherapeutic agent","volume":"20","author":"Marriott","year":"1999","journal-title":"Immunol. Today"},{"issue":"2","key":"10.1016\/j.bioorg.2020.104218_b0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. Part C: Embryo Today: Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2020.104218_b0015","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2020.104218_b0020","series-title":"Dark Remedy: The Impact of Thalidomide And its Revival as A Vital Medicine","author":"Stephens","year":"2009"},{"issue":"16","key":"10.1016\/j.bioorg.2020.104218_b0025","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.ejca.2004.07.023","article-title":"Thalidomide in solid tumours: the resurrection of an old drug","volume":"40","author":"Sleijfer","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: the tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/157488512800389164","article-title":"Thalidomide: a banned drug resurged into future anticancer drug","volume":"7","author":"Ali","year":"2012","journal-title":"Curr. Drug Therapy"},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2020.104218_b0045","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1086\/498216","article-title":"Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation","volume":"192","author":"Haslett","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.bioorg.2020.104218_b0050","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2020.104218_b0055","series-title":"Angiogenesis-dependent diseases, Seminars in oncology","first-page":"536","author":"Folkman","year":"2001"},{"key":"10.1016\/j.bioorg.2020.104218_b0060","series-title":"IMiDs: a novel class of immunomodulators, Seminars in oncology","first-page":"24","author":"Knight","year":"2005"},{"issue":"7\u20138","key":"10.1016\/j.bioorg.2020.104218_b0065","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0070","first-page":"222","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2020.104218_b0075","doi-asserted-by":"crossref","unstructured":"A.C.L. Leite, F.F. Barbosa, M.V. de Oliveira Cardoso, D.R. Moreira, L.C.D. Co\u00ealho, E.B. da Silva, G.B. de Oliveira Filho, V.M.O. de Souza, V.R.A. Pereira, L.d.C. Reis, Phthaloyl amino acids as anti-inflammatory and immunomodulatory prototypes, Medicinal Chem. Res. 23(4) (2014) 1701\u20131708.","DOI":"10.1007\/s00044-013-0730-1"},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bmcl.2012.10.071","article-title":"Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity","volume":"23","author":"Ruchelman","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0085","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1208\/aapsj070103","article-title":"Properties of thalidomide and its analogues: implications for anticancer therapy","volume":"7","author":"Teo","year":"2005","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3816\/CLM.2006.n.004","article-title":"Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma","volume":"6","author":"Suppiah","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.bioorg.2020.104218_b0095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/OTT.S34498","article-title":"Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma","volume":"6","author":"Terpos","year":"2013","journal-title":"OncoTargets Therapy"},{"issue":"33","key":"10.1016\/j.bioorg.2020.104218_b0100","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.2174\/09298673113209990198","article-title":"Thalidomide\u2013a notorious sedative to a wonder anticancer drug","volume":"20","author":"Zhou","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2020.104218_b0105","first-page":"1888","article-title":"A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer","volume":"7","author":"Figg","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2020.104218_b0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.biopha.2012.04.005","article-title":"Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice","volume":"66","author":"de Souza","year":"2012","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0753-3322(02)00177-4","article-title":"Thalidomide, an antiangiogenic agent with clinical activity in cancer","volume":"56","author":"Ng","year":"2002","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0120","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-007-0521-9","article-title":"Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors","volume":"61","author":"Varker","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/COC.0b013e31820dbf56","article-title":"Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma","volume":"35","author":"Ang","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2020.104218_b0135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2020.104218_b0140","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0145","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V99.3.834","article-title":"Efficacy and safety of thalidomide in patients with acute myeloid leukemia","volume":"99","author":"Steins","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bioorg.2020.104218_b0150","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/187221411797265890","article-title":"Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications","volume":"5","author":"Bodera","year":"2011","journal-title":"Recent Pat. Endocr., Metab. Immune Drug Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2020.104218_b0160","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00001813-200011000-00002","article-title":"Thalidomide in the treatment of cancer","volume":"11","author":"Adlard","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bioorg.2020.104218_b0165","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","author":"Anderson","year":"2005","journal-title":"Seminars Hematol. Elsevier"},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0170","doi-asserted-by":"crossref","DOI":"10.15436\/2381-1404.15.008","article-title":"Novel mechanisms of action for immunomodulatory drugs (IMiDs) against multiple myeloma: from a tragedy to a therapy","volume":"2","author":"Dai","year":"2015","journal-title":"Int. J. Hematol. Therapy"},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12032-010-9527-y","article-title":"Mechanism of action of immunomodulatory agents in multiple myeloma","volume":"27","author":"Reske","year":"2010","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428190109099330","article-title":"Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma","volume":"42","author":"Avigdor","year":"2001","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.bioorg.2020.104218_b0185","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmech.2017.07.073","article-title":"Novel 4\/3-((4-oxo-5-(2-oxoindolin-3-ylidene) thiazolidin-2-ylidene) amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies","volume":"139","author":"Eldehna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2018.06.017","article-title":"Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFR WT and EGFR T790M inhibitors and apoptosis inducers","author":"Gaber","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0195","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11030-017-9776-1","article-title":"Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents","volume":"21","author":"El-Naggar","year":"2017","journal-title":"Mol. Diversity"},{"key":"10.1016\/j.bioorg.2020.104218_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102944","article-title":"Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR\/HER2 inhibitors and apoptosis inducers","volume":"88","author":"Elmetwally","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0205","first-page":"103422","article-title":"Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","author":"Mahdy","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bioorg.2016.05.006","article-title":"Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo [3, 4-b] pyridine derivatives as potential anticancer agents","volume":"67","author":"Eissa","year":"2016","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104218_b0215","first-page":"195","article-title":"Design and discovery of novel quinoxaline derivatives as dual DNA intercalators and topoisomerase II inhibitors","volume":"18","author":"Eissa","year":"2018","journal-title":"Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"10.1016\/j.bioorg.2020.104218_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2018.06.004","article-title":"Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2020.104218_b0225","doi-asserted-by":"crossref","first-page":"1900123","DOI":"10.1002\/ardp.201900123","article-title":"Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors","volume":"352","author":"Eissa","year":"2019","journal-title":"Arch. Pharm."},{"issue":"10","key":"10.1016\/j.bioorg.2020.104218_b0230","doi-asserted-by":"crossref","first-page":"1900113","DOI":"10.1002\/ardp.201900113","article-title":"Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch. Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2020.104218_b0235","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1039\/C9RA10094F","article-title":"Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5 (4 H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site","volume":"10","author":"El-Naggar","year":"2020","journal-title":"RSC Adv."},{"issue":"17","key":"10.1016\/j.bioorg.2020.104218_b0240","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/jm9603328","article-title":"Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity","volume":"39","author":"Muller","year":"1996","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104218_b0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bmc.2003.11.007","article-title":"Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer","volume":"12","author":"Capitosti","year":"2004","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2020.104218_b0250","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1016\/j.bmcl.2005.08.086","article-title":"Angiogenesis inhibitors derived from thalidomide","volume":"15","author":"Noguchi","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2020.104218_b0255","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1016\/j.bmcl.2007.08.042","article-title":"Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling","volume":"17","author":"Stewart","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2020.104218_b0260","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cclet.2008.05.044","article-title":"Synthesis and biological evaluation of novel thalidomide analogues as potential anticancer drugs","volume":"19","author":"Wang","year":"2008","journal-title":"Chin. Chem. Lett."},{"issue":"22","key":"10.1016\/j.bioorg.2020.104218_b0265","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1016\/j.bmc.2008.09.071","article-title":"Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice","volume":"16","author":"Zahran","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2020.104218_b0270","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.ejmech.2009.03.018","article-title":"Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-\u03b1 production","volume":"44","author":"Bra\u00f1a","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0275","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2010.12.031","article-title":"Design, synthesis and biological evaluation of new thalidomide analogues as TNF-\u03b1 and IL-6 production inhibitors","volume":"21","author":"Chaulet","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2020.104218_b0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.biopha.2012.05.001","article-title":"Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10","volume":"66","author":"Mazzoccoli","year":"2012","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bmcl.2012.10.106","article-title":"Synthesis and anti-angiogenic activity of benzothiazole, benzimidazole containing phthalimide derivatives","volume":"23","author":"Nagarajan","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104218_b0290","doi-asserted-by":"crossref","unstructured":"P.M. Da Costa, M.P. da Costa, A.A. Carvalho, S.M.T. Cavalcanti, M.V. de Oliveira Cardoso, G.B. de Oliveira Filho, D. de Ara\u00fajo Viana, F.V. Fechine-Jamacaru, A.C.L. Leite, M.O. de Moraes, Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives, Chemico-biological Interact. 239 (2015) 174\u2013183.","DOI":"10.1016\/j.cbi.2015.06.037"},{"key":"10.1016\/j.bioorg.2020.104218_b0295","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2015.04.041","article-title":"Design, synthesis and structure\u2013activity relationship of phthalimides endowed with dual antiproliferative and immunomodulatory activities","volume":"96","author":"de Oliveira Cardoso","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0300","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2015.04.051","article-title":"1, 3, 4-Oxadiazoles: an emerging scaffold to target growth factors, enzymes and kinases as anticancer agents","volume":"97","author":"Bajaj","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0305","doi-asserted-by":"crossref","unstructured":"W. Caneschi, K.B. Enes, C.C. de Mendon\u00e7a, F. de Souza Fernandes, F.B. Miguel, J. da Silva Martins, M. Le Hyaric, R.R. Pinho, L.M. Duarte, M.A.L. de Oliveira, Synthesis and anticancer evaluation of new lipophilic 1, 2, 4 and 1, 3, 4-oxadiazoles, Eur. J. Med. Chem. 165 (2019) 18\u201330.","DOI":"10.1016\/j.ejmech.2019.01.001"},{"key":"10.1016\/j.bioorg.2020.104218_b0310","doi-asserted-by":"crossref","first-page":"103569","DOI":"10.1016\/j.bioorg.2020.103569","article-title":"Synthesis of a novel series of (Z)-3, 5-disubstituted thiazolidine-2, 4-diones as promising anti-breast cancer agents","author":"El-Kashef","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2020.104218_b0315","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103115","article-title":"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPAR\u03b3 and SUR agonists","volume":"91","author":"El-Zahabi","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0325","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0968-0896(01)00366-2","article-title":"Synthesis and aldose reductase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones","volume":"10","author":"Bruno","year":"2002","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2020.104218_b0330","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1016\/j.bmcl.2007.04.109","article-title":"Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones","volume":"17","author":"Maccari","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104218_b0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molstruc.2018.04.010","article-title":"Synthesis, docking, QSAR, ADMET and antimicrobial evaluation of new quinoline-3-carbonitrile derivatives as potential DNA-gyrase inhibitors","volume":"1166","author":"El-Gamal","year":"2018","journal-title":"J. Mol. Struct."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104218_b0340","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.bmc.2017.01.015","article-title":"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPAR\u03b3 and SUR agonists","volume":"25","author":"Ibrahim","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2020.104218_b0345","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1016\/j.bmc.2017.07.015","article-title":"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4 (3H)-one derivatives as potential PPAR\u03b3 and SUR agonists","volume":"25","author":"Ibrahim","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0350","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10241220601004924","article-title":"Syntheses, crystal structures and dynamic 1HNMR study of diastereotopic CH2 protons in several new phosphoric triamides","author":"Gholivand","year":"2006","journal-title":"Main Group Chem. Taylor & Francis"},{"key":"10.1016\/j.bioorg.2020.104218_b0355","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3998\/ark.5550190.0012.815","article-title":"A novel synthesis of chloroacetamide derivatives via C-amidoalkylation of aromatics by 2-chloro-N-(2, 2, 2-trichloro-1-hydroxyethyl) acetamide","volume":"8","author":"Aizina","year":"2011","journal-title":"Arkivoc"},{"key":"10.1016\/j.bioorg.2020.104218_b0360","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1590\/S0103-50532005000100018","article-title":"Unexpected diastereotopic behaviour in the 1H NMR spectrum of 1, 4-dihydropyridine derivatives triggered by chiral and prochiralcentres","volume":"16","author":"DaSilva","year":"2005","journal-title":"J. Braz. Chem. Soc."},{"issue":"12","key":"10.1016\/j.bioorg.2020.104218_b0365","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.crci.2015.09.005","article-title":"Ultrasound-assisted, one-pot, three-component synthesis and antibacterial activities of novel indole derivatives containing 1, 3, 4-oxadiazole and 1, 2, 4-triazole moieties","volume":"18","author":"Shi","year":"2015","journal-title":"C. R. Chim."},{"issue":"16","key":"10.1016\/j.bioorg.2020.104218_b0370","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1016\/j.bmcl.2010.06.125","article-title":"Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1, 2, 4-triazolo-[3, 4-b]-1, 3, 4-thiadiazole and 1, 3, 4-oxadiazole derivatives of isoniazid","volume":"20","author":"Gilani","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2020.104218_b0375","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0378-4274(85)90046-3","article-title":"Toxicity determined in vitro by morphological alterations and neutral red absorption","volume":"24","author":"Borenfreund","year":"1985","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0380","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.bioorg.2020.104218_b0385","doi-asserted-by":"crossref","first-page":"1900178","DOI":"10.1002\/ardp.201900178","article-title":"Benzoxazole\/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2020.104218_b0390","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.bioorg.2020.104218_b0395","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"issue":"11","key":"10.1016\/j.bioorg.2020.104218_b0400","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.2042-7158.1997.tb06055.x","article-title":"Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay","volume":"49","author":"Thabrew","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.104218_b0405","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bioorg.2018.01.034","article-title":"Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer","volume":"77","author":"Almahli","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0410","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-5793(00)01246-1","article-title":"Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16","volume":"469","author":"Inoue","year":"2000","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104218_b0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/vim.2009.0089","article-title":"Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity","volume":"23","author":"Talaat","year":"2010","journal-title":"Viral Immunol."},{"key":"10.1016\/j.bioorg.2020.104218_b0420","unstructured":"mybiosource.com\/, MyBioSource ELISA Test Kits, 2019. https:\/\/www.mybiosource.com\/human-elisa-kits\/casp8\/2513072#QLAPP_MBS2513072_TD (accessed May 2018).."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104218_b0425","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biomag.2014.03.002","article-title":"Novel thalidomide analogs: Anti-angiogenic and apoptotic effects on Hep-G2 and MCF-7 cancer cell lines","volume":"4","author":"Talaat","year":"2014","journal-title":"Biomed. Aging Pathol."},{"issue":"5","key":"10.1016\/j.bioorg.2020.104218_b0430","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1242\/jcs.113.5.753","article-title":"Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies","volume":"113","author":"Wang","year":"2000","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0435","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/14756366.2018.1547286","article-title":"Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents","volume":"34","author":"Eldehna","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104218_b0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/ic701735q","article-title":"Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes","volume":"47","author":"Lo","year":"2008","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2020.104218_b0445","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.0c00094","article-title":"Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer","author":"Eldehna","year":"2020","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820315157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820315157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:43:38Z","timestamp":1763567018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820315157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":89,"alternative-id":["S0045206820315157"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104218","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104218"}}